BioAmber Prices $11 mn Underwritten Offering of Common Stock
BioAmber Inc (BIOA) has priced an underwritten public offering of an aggregate of 14,666,667 shares of common stock of the company, to be sold together in fixed combination with warrants to purchase up to 14,666,667 shares of common stock of the company at a price to the public of $0.75 per share and associated warrant.
The closing of the offering is expected to occur on or about 11 August 2017.
The warrants have an exercise price of $0.75 and a term of five (5) years, exercisable upon the date of issuance. The aggregate gross proceeds to the company (assuming no exercise of the warrants) are $11 million, before deducting underwriting discounts and commissions and estimated offering expenses.
The company has granted to the underwriters a 30-day option (over-allotment option) to purchase up to an additional 2.2 million shares of common stock and/or warrants to purchase up to 2.2 million shares of common stock of the company, for potentially additional aggregate proceeds to the company of up to approximately $1.65 million (assuming no exercise of the warrants) before deducting underwriting discounts and commissions and estimated offering expenses.
In the event the over-allotment option is exercised in full, the aggregate gross proceeds to the company (assuming no exercise of the warrants) will be approximately $12.65 million.
Rodman & Renshaw, a unit of HC Wainwright & Co is acting as the sole book-running manager in connection with this offering.
2026-09-28
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
AstraZeneca and CSPC Strengthen Biologics Manufacturing Partnership in China
-
Symrise Launches “Care & Wellness” Division to Strengthen Beauty–Health Integration
-
BASF Launches Global Expansion Plan for Aroma Ingredients
-
BASF Launches Global Expansion Plan for Aroma Ingredients
-
Geopolitical Conflict Drives Up Chemical Costs: The Industry Signal Behind DuPont’s Upgraded Outlook
-
Middle East Conflict Pushes Up Costs as Dow Warns the Chemical Industry Faces a Tougher Period
-
Supply Chain Resilience Reshapes Chemical Competition: What Lies Behind BASF’s Stable Outlook
-
Hengli Petrochemical’s Dalian Refinery Sanctioned by the U.S.
-
BASF Raises North American Nylon Products by $0.08/lb, Fourth Price Increase in Six Months
-
One Ton of Fake Plastic Nearly Burned China’s Manufacturing Reputation—Wanhua Chemical Exposes the Underbelly of the Chemical Black Market
Recommend Reading
-
Givaudan to Build New Fragrance Compounding Facility in Pedro Escobedo, Mexico
-
$15 Billion Invested in China: AstraZeneca Builds an “Innovation Hub” While Some Are Still Waiting for the Windfall
-
“Falling Revenue, Soaring Profits”: Is AkzoNobel’s Financial Alchemy Real Muscle—or Just Smoke and Mirrors?
-
BASF's Zhanjiang Plant Steam Cracking Unit Commences Operation
-
Nouryon's Production Facilities in China Have Obtained Halal Certification for Personal Care Ingredients
-
This week, the domestic anhydrous hydrogen fluoride market maintained a high-level consolidation operation (3.16-3.19)
-
Below the 10,000 RMB mark! Acrylic acid continues to fall, how much further can it go?
-
Supply-side Disruptions Continue, Lithium Carbonate Prices Keep Rising
-
Premium Global Chemical Sourcing Requests (1-5 Dec 2025)
-
Business Society’s ABS Market Outlook on August 19, 2026: Clearly Upward